Toposar Alternatives Compared
| Toposar (etoposide) | Nivolumab | Keytruda (pembrolizumab) |
|
|---|
| Toposar (etoposide) | Nivolumab | Keytruda (pembrolizumab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hodgkin's Lymphoma, Small Cell Lung Cancer, Ovarian Cancer, Testicular Cancer, Cancer. Toposar may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Head and Neck Cancer, Esophageal Carcinoma, Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Related suggestions Hodgkin's Lymphoma
|
|||||||
| More about Toposar (etoposide) | More about Nivolumab | More about Keytruda (pembrolizumab) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Nivolumab has an average rating of 5.6 out of 10 from a total of 130 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 44% reported a negative effect. |
Keytruda has an average rating of 4.8 out of 10 from a total of 244 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 50% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Keytruda prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
||||||||
| Brand Names | ||||||||||
| Other etoposide brands include: Etopophos | Opdivo |
N/A |
||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
11 hours |
640.8 hours |
624 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 450 drugs are known to interact with Toposar:
|
A total of 406 drugs are known to interact with Nivolumab:
|
A total of 406 drugs are known to interact with Keytruda:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
December 22, 2014 |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.